Core Viewpoint - The controlling shareholder, Hualan Electromechanical, plans to increase its stake in Hualan Co., Ltd. based on confidence in the company's long-term investment value and stable future development [1] Group 1: Shareholder Actions - Hualan Electromechanical intends to increase its shareholding in Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. within a six-month period from November 6, 2025, to May 5, 2026, excluding the trading window [1] - The planned increase in shareholding will be through centralized bidding, with an investment amount ranging from RMB 30 million to RMB 60 million [1] - The maximum purchase price is set at RMB 58.08 per share, and the total number of shares to be acquired will not exceed 2% of the company's total issued shares, excluding those held in the repurchase special securities account [1]

智通财经APP讯，华兰股份(301093.SZ)公告，公司控股股东江阴华兰机电科技有限公司(简称"华兰机 电")计划自2025年11月6日至2026年5月5日通过集中竞价交易方式增持公司股份，增持金额不低于人民 币3000万元且不超过人民币6000万元，增持价格不超过58.08元/股。累计增持股份数量不超过公司已发 行股份总数(届时将剔除存放于回购专用证券账户的股份数量)的2.00%。 ...

Core Viewpoint - Hualan Co., Ltd. plans to increase its shareholding through a centralized bidding transaction, reflecting confidence in the company's long-term investment value and stable future development [1] Summary by Relevant Sections Shareholding Increase Plan - Hualan Electromechanical intends to increase its shareholding within six months from the announcement date, with an investment amount between RMB 30 million and RMB 60 million [1] - The maximum purchase price is set at RMB 58.08 per share, with the total number of shares to be acquired not exceeding 2% of the company's total issued shares [1] Current Shareholding Status - Before the planned increase, Jiangyin Hualan Electromechanical Technology Co., Ltd. holds approximately 36.76 million shares, accounting for 22.39% of the total share capital of about 164 million shares [1] - This holding represents 22.4% of the total voting shares, excluding around 100,000 shares held in the company's repurchase special securities account [1] Financial Performance - For the first half of 2025, Hualan Co., Ltd.'s revenue composition shows that the pharmaceutical manufacturing sector accounts for 99.07%, while other businesses contribute 0.93% [1] - As of the report date, the market capitalization of Hualan Co., Ltd. is RMB 6.7 billion [1]

人民财讯11月5日电，华兰股份（301093）11月5日公告，控股股东江阴华兰机电科技有限公司(简称"华 兰机电")计划通过集中竞价交易方式增持公司股份，增持金额不低于3000万元且不超过6000万元，增持 价格不超过58.08元/股，本次累计增持股份数量不超过公司已发行股份总数(届时将剔除存放于回购专用 证券账户的股份数量)的2%。 ...

特别提示： 1、江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"） 于近日收到了控股股东江阴华兰机电科技有限公司（以下简称"华兰机电"）出 具的《关于增持江苏华兰药用新材料股份有限公司股份计划的告知函》，华兰机 电基于对公司长期投资价值的认可以及未来持续稳定发展的信心，计划自本公 告披露之日起 6 个月内（2025 年 11 月 6 日至 2026 年 5 月 5 日，窗口期除外）， 通过集中竞价交易方式增持公司股份，增持金额不低于人民币 3,000 万元且不 超过人民币 6,000 万元，增持价格不超过 58.08 元/股，本次累计增持股份数量 不超过公司已发行股份总数（届时将剔除存放于回购专用证券账户的股份数量） 的 2.00%。本次华兰机电增持公司股份符合《上市公司收购管理办法》等相关 法律、法规规定的可以免于发出要约的情形。 2、本次增持计划可能存在因资本市场情况发生变化或目前尚无法预判的其 他风险因素导致增持计划的实施无法达到预期的风险。如增持计划实施过程中 出现上述风险情形，公司将及时督促增持主体履行信息披露义务。敬请广大投 资者注意投资风险。 一、 本次增持计划的增持主体基本情况 ...

华兰股份公告，控股股东江阴华兰机电科技有限公司拟自2025年11月6日至2026年5月5日，通过集中竞 价增持公司股份，增持金额不低于3000万元且不超过6000万元，增持价格不超过58.08元/股，累计增持 比例不超过公司已发行股份总数的2.00%；本次增持前其持股3676.4万股，占总股本22.39%。 ...

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a significant increase in its stock price, rising by 5.32% to 41.20 CNY per share, with a total market capitalization of 6.765 billion CNY [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%), conventional rubber stoppers (48.50%), and others (2.43%) [1] - The company is located in Jiangyin City, Jiangsu Province, and was established on June 4, 1992, with its stock listed on November 1, 2021 [1] Group 2 - From the perspective of fund holdings, Hualan Co., Ltd. is a significant investment for the Galaxy Fund, with the Galaxy Kangle Stock A fund holding 225,500 shares, which represents 4.88% of the fund's net value [2] - The Galaxy Kangle Stock A fund has reduced its holdings by 130,300 shares in the third quarter, while it has achieved a floating profit of approximately 469,100 CNY as of the report date [2] - The fund has a total scale of 156 million CNY and has reported a year-to-date return of 24.83%, ranking 2158 out of 4216 in its category [2]

Core Viewpoint - Hualan Co., Ltd. has repurchased a total of 2.9757 million shares, representing 1.81% of the company's total share capital, with a total expenditure of approximately 99.9795 million yuan as of October 31, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through a dedicated securities account via centralized bidding [1] - The highest transaction price was 34.800 yuan per share, while the lowest was 28.700 yuan per share [1] - The total amount of funds used for the repurchase, excluding transaction fees, was 99.9795 million yuan [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-110 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Core Viewpoint - Hualan Co., Ltd. is a significant player in the domestic market for injectable drug packaging materials, with strengths in technology research and product quality [1] Group 1: Business Performance - In Q3 2025, Hualan's revenue reached 441 million yuan, ranking 34th in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The main business composition includes film-coated rubber stoppers at 152 million yuan (49.07%) and conventional rubber stoppers at 150 million yuan (48.50%) [2] - The net profit for the same period was 53.23 million yuan, also ranking 34th in the industry, with the industry leader, Lepu Medical, achieving 999.6 million yuan [2] Group 2: Financial Ratios - Hualan's debt-to-asset ratio was 13.48% in Q3 2025, up from 9.77% year-on-year, which is lower than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 38.92%, slightly down from 39.15% year-on-year, and below the industry average of 48.78% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.09% to 13,300, while the average number of circulating A-shares held per shareholder increased by 49.59% to 11,800 [5] - Hualan's main business is expected to grow steadily, with projected revenue growth of 15-20% in 2025 due to increased demand from pharmaceutical clients and high-end orders [5] Group 4: Management and Compensation - The chairman, Hua Yimin, received a salary of 1.03 million yuan in 2024, unchanged from 2023 [4]